// App-Quantinova.ai

4504 : Clofarabine/Cyclophosphamide (ClofCy) for Debulking refractory Acute Leukemias Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Researchers

Presenter

  • Alexandra Boehm

Principal Investigators

  • Peter Schellongowski

  • Peter Kalhs

  • Peter Valent

  • Wolfgang R Sperr

Medical Centers

  • Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria

  • Division of bone marrow transplantation, Medical University of Vienna, Vienna, Austria

  • Transfusion Medicine, Medical University of Vienna, Vienna, Austria

  • Department of Internal Medicine I, Bone Marrow Transplantation Unit, Medical University of Vienna, Vienna, Austria

  • Medical University of Vienna, Vienna, Austria

Locations

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Graft-versus-host disease

  • Acute myelocytic leukemia

Biomarkers

  • Alanine transaminase

  • Aspartate aminotransferase

  • Breakpoint Cluster Region

  • Cluster of Differentiation 34

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Clofarabine

  • Melphalan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved